BridgeBio Pharma, Inc.
BBIONASDAQHealthcare● Active
$67.66
+$0.05(+0.07%)
Market Cap$13.3B
P/E Ratio—
52W High$84.94
52W Low$37.69
BridgeBio Pharma, Inc. (BBIO) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BBIO · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.50B | $0.22B | $0.01B | $0.08B | $0.07B |
| Cost of Revenue | $0.03B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.47B | $0.22B | $0.01B | $0.07B | $0.07B |
| Gross Margin %(computed) | 94.37% | 98.25% | 73.71% | 95.58% | 95.53% |
| Operating Expenses | |||||
| R&D Expenses | $0.48B | $0.51B | $0.46B | $0.40B | $0.45B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.04B | $0.81B | $0.61B | $0.59B | $0.64B |
| Operating Income | ($0.57B) | ($0.59B) | ($0.61B) | ($0.51B) | ($0.58B) |
| Operating Margin %(computed) | -113.35% | -267.22% | — | -659.65% | -827.12% |
| Interest Income | $0.02B | $0.02B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.05B | $0.10B | $0.08B | $0.08B | $0.05B |
| Income Before Tax | ($0.73B) | ($0.54B) | ($0.65B) | ($0.48B) | ($0.59B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.73B) | ($0.54B) | ($0.64B) | ($0.48B) | ($0.56B) |
| Net Margin %(computed) | -145.26% | -241.44% | — | -619.70% | -806.90% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.79 | $-2.88 | $-3.95 | $-3.35 | $-3.90 |
| Wtd Avg Shares | 0.20B | 0.19B | 0.16B | 0.15B | 0.14B |
| EBITDA | ($0.67B) | ($0.44B) | ($0.57B) | ($0.40B) | ($0.53B) |
| EBITDA Margin %(computed) | -134.02% | -196.86% | — | -511.85% | -765.73% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more BridgeBio Pharma, Inc. data
About BridgeBio Pharma, Inc. (BBIO) Income Statement
BridgeBio Pharma, Inc. (BBIO) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BBIO reported revenue of $0.50B, gross profit of $0.47B (gross margin 94.37%), and net income of ($0.73B) — a net profit margin of -145.26%.
Frequently asked questions
BBIO · 4 questionsBridgeBio Pharma, Inc. (BBIO) reported revenue of $0.50B for 2025, up 126.3% year-over-year.
BBIO revenueBBIO salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08